Mucoviscidosis in adults;La mucoviscidose de l'adulte

Presse Medicale

Volumn 31, Issue 6, 2002, Pages 263-270

  Stern, M ^a   Picard, C ^a   Grenet, D ^a  

^a FOCH HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; TRANSMEMBRANE CONDUCTANCE REGULATOR;

ANTIBIOTIC THERAPY; AUTOSOMAL RECESSIVE DISORDER; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BRONCHODILATATION; CLINICAL FEATURE; CYSTIC FIBROSIS; DRUG EFFICACY; FRANCE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; LUNG TRANSPLANTATION; MUSCLE EXERCISE; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; RESPIRATORY FAILURE; REVIEW; SURVIVAL TIME; SWEAT TEST;

ADULT; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DIAGNOSIS, DIFFERENTIAL; HUMANS; INFUSIONS, INTRAVENOUS; LUNG TRANSPLANTATION; PATIENT COMPLIANCE; PROGNOSIS; QUALITY OF LIFE; RESPIRATORY INSUFFICIENCY;

EID: 0037116795     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Cystic fibrosis: Current survival and population estimates to the year 2000
2. Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis
3. Higher bioelectric potentials due to decreased chloride absorption in the sweat glands of patients with cystic fibrosis
4. Identification of the cystic fibrosis gene: Chromosome walking and jumping
5. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA
6. Identification of the cystic fibrosis gene: Genetic analysis
7. Cystic fibrosis: State of the art
8. Worldwide survey of the F508 mutation: Report from the cystic fibrosis genetic analysis consortium
9. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis
10. Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations
11. Genotype and phenotype in cystic fibrosis
12. Cystic fibrosis: A new outlook 70 patients above 25 years of age
13. Cystic fibrosis in adults. 75 cases and a review of 232 cases in the litterature
14. Cystic fibrosis in adolescents and adults
15. Clinical features, survival rate and prognostic factors in young adults with cystic fibrosis
16. La mucoviscidose à l'âge adulte
17. Caractéristiques et spécificités de la mucoviscidose chez l'adulte: Évolution d'une maladie de l'enfance ou maladie de découverte récente?
18. Gastrointestinal manifestations of cystic fibrosis: A review
19. Natural history of liver disease in cystic fibrosis
20. Analysis of risk factors for the development of liver disease associated with cystic fibrosis
21. Clinical and genetic risk factors for cystic fibrosis-related liver disease
22. Glucose tolerance in patients with cystic fibrosis: Five year prospective study
23. Diagnosis of cystic fibrosis related diabetes: A selective approach in performing the oral glucose tolerance test based on a combination of clinical and biochemical criteria
24. Diabetes mellitus in cystic fibrosis: Effect of insulin therapy on lung function and infections
25. Diabetes mellitus in Danish cystic fibrosis patients: Prevalence and late diabetic complications
26. Obstructive azoospermia as a diagnostic criterion for the cystic fibrosis syndrome
27. Fertilité et reproduction
28. Fertility in men with cystic fibrosis. An update on current surgical practices and outcomes
29. Pregnancy in cystic fibrosis. Fetal and maternal outcome
30. Pregnancy and cystic fibrosis. A case-controlled study
31. Low bone density in adults with cystic fibrosis
32. Genetic and clinical features of patients with cystic fibrosis diagnosed after the age of 16 years
33. Clinical features associated with a delayed diagnosis of cystic fibrosis
34. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens
35. Proportion of cystic fifrosis gene mutations not detected by routine testing in men with obstructive azoospermia
36. Pulmonary function and clinical observations in men with congenital bilateral absence of the vas deferens
37. Abnormal distribution of cystic fibrosis F508 allele in adults with chronic bronchial hypersecretion
38. Increased incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis
39. CFTR gene mutations in adult with disseminated bronchiectasis
40. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis
41. Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis
42. Sweat tests to diagnose cystic fibrosis in adults
43. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis
44. Intermediate-range sweat chlroride concentration and pseudomonas bronchitis. A cystic fibrosis with preservation of exocrine pancreatic function
45. Measurements of nasal transepithelial electric potential differences in normal human subjects in vivo
46. Nasal potential difference: A clinical diagnostic test for cystic fibrosis
47. Nasal potential difference in cystic fibrosis patients presenting borderline sweat test
48. Normal sweat chloride values do not exclude the diagnosis of cystic fibrosis
49. Les mutations de la mucoviscidose: Du genotype au phénotype
50. Association of nonsense mutation (W1282X), the most common mutation in the ashkenazi jewish cystic fibrosis patients in Israel, with presentation of severe disease
51. Cystic fibrosis
52. Treatment of cystic fibrosis in the adult
53. Chest physical therapy management of cystic fibrosis. A meta-analysis
54. Spécificités et prise en charge de l'alteinte pulmonaire au cours de la mucoviscidose à l'age adulte
55. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
56. Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by early treatment
57. Transplantation pulmonaire dans la mucoviscidose de l'adulte. Recommandations pour la sélection des candidats
58. Fatty acids in cystic fibrosis
59. Understanding non-compliance with treatment in adults with cystic fibrosis